Gamida Cell (NASDAQ:GMDA) Raised to Hold at Zacks Investment Research

Gamida Cell (NASDAQ:GMDA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “Gamida Cell Ltd. is a biopharmaceutical company. It focuses on developing cell therapies to cure cancer and rare and serious hematologic diseases. The company’s product pipeline consists of NiCord and NAM-NK which are in clinical stage. It operates primarily in the United States, the European Union and internationally. Gamida Cell Ltd. is headquartered in Jerusalem, Israel. “

A number of other research analysts have also weighed in on GMDA. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of Gamida Cell in a report on Tuesday, December 10th. JMP Securities began coverage on Gamida Cell in a report on Friday, September 20th. They issued an “outperform” rating and a $16.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $14.25.

Shares of GMDA stock traded up $0.09 during mid-day trading on Tuesday, reaching $4.53. The stock had a trading volume of 41,100 shares, compared to its average volume of 43,744. The business’s fifty day moving average is $4.72 and its 200-day moving average is $4.43. The company has a current ratio of 7.61, a quick ratio of 7.60 and a debt-to-equity ratio of 0.09. The firm has a market cap of $115.06 million, a price-to-earnings ratio of -0.43 and a beta of 1.64. Gamida Cell has a 1-year low of $2.93 and a 1-year high of $15.00.

Gamida Cell (NASDAQ:GMDA) last announced its quarterly earnings data on Wednesday, November 13th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. On average, analysts forecast that Gamida Cell will post -1.12 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. Millennium Management LLC boosted its stake in shares of Gamida Cell by 4.6% in the third quarter. Millennium Management LLC now owns 69,077 shares of the company’s stock worth $299,000 after buying an additional 3,017 shares during the last quarter. Phoenix Holdings Ltd. purchased a new stake in shares of Gamida Cell in the third quarter worth about $121,000. Royal Bank of Canada purchased a new stake in shares of Gamida Cell in the second quarter worth about $71,000. Noked Capital LTD purchased a new position in Gamida Cell during the second quarter worth approximately $1,035,000. Finally, EcoR1 Capital LLC purchased a new position in Gamida Cell during the second quarter worth approximately $265,000. 23.87% of the stock is currently owned by institutional investors and hedge funds.

Gamida Cell Company Profile

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Read More: Real Estate Investment Trust (REIT) ETF

Get a free copy of the Zacks research report on Gamida Cell (GMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.